Lupin Healthcare (UK) Limited, a wholly owned subsidiary of global pharmaceutical leader Lupin Limited, has announced the acquisition of Renascience Pharma Limited, a UK-based pharmaceutical company specializing in four key specialty products addressing unmet medical needs.
With the acquisition, Lupin Healthcare (UK) Limited gains complete ownership of Renascience, which will now operate as its subsidiary. This move strengthens Lupin’s position in the UK’s branded pharmaceutical market. It also expands its portfolio to better serve patients and healthcare providers.
Expanding the Specialty Medicines Portfolio
Renascience brings a strong portfolio of specialty medicines. It includes branded injectable cephalosporins for infectious diseases. It also offers a topical treatment for ear pain. Additionally, it features a branded quinazoline-like diuretic for cardiovascular and renal conditions. By integrating these products into its existing lineup, Lupin enhances its ability to provide critical medications to patients across the UK.
Leadership Perspectives on the Acquisition
Fabrice Egros, President of Corporate Development at Lupin, emphasized, “Lupin has built a highly successful branded business in the UK, delivering significant value to patients and the NHS. This acquisition enables us to further expand our branded medicine portfolio, address unmet medical needs, and reinforce our mission of providing accessible and sustainable healthcare solutions.”
Eric Che, Co-founder and Director of Renascience, stated, “Renascience was founded to improve patient access to specialty and critical medicines. We are incredibly proud of our impact so far. As we looked toward the future, it was essential to find a partner that could build on our success and expand our reach. Lupin’s culture, expertise, and capabilities make it the perfect fit to take Renascience to the next stage of growth.”
Advancing Patient Care in the UK
With this acquisition, Lupin continues to strengthen its commitment to delivering high-quality, innovative healthcare solutions. According to the press release, Lupin will leverage Renascience’s expertise and product lineup. The company aims to enhance treatment options and improve patient outcomes. Additionally, Lupin will support the NHS in delivering efficient and sustainable healthcare services.
